AZEVAN PHARMACEUTICALS INC

Company Information

Company Name
AZEVAN PHARMACEUTICALS INC
Address
116 RESEARCH DR
BETHLEHEM, PA, 18015-4734
Phone
1 610-758-3620
URL
n/a
DUNS
604182118
Number of Employees
7
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$449,195.00
2
SBIR Phase II
$1,794,075.00
2
STTR Phase I
$241,071.00
3
STTR Phase II
$498,684.00
1

Award List

  1. New Drugs for Stress-related Affective Illness

    Amount: $349,195.00

    DESCRIPTION (provided by applicant): Vasopressin (AVP) antagonists represent a novel therapeutic class for the treatment of depression. The potential utility of these compounds has emerged from observ ...

    SBIR Phase I 2010 Department of Health and Human Services
  2. N/A

    Amount: $100,000.00

    N/A

    STTR Phase I 2000 Department of Health and Human Services
  3. A NEW DRUG FOR DEPRESSION

    Amount: $100,000.00

    Long Term Goals: Serenix Pharmaceuticals (SP) will develop drugs for the treatment of CNS disorders. Strategy: SP acquired a series of vasopressin receptor antagonists from Eli Lilly and Company and h ...

    SBIR Phase I 2002 Department of Health and Human Services
  4. A Potential New Drug for Depression

    Amount: $0.00

    DESCRIPTION (provided by applicant): A Potential New Drug for Depression, an active SBIR Phase IIa award. The requested funds will allow additional characterization studies of three newly discovered m ...

    SBIR Phase II 2009 Department of Health and Human Services
  5. TREATING SELF-ABUSE IN AUTISM AND MENTAL RETARDATION

    Amount: $0.00

    Serenix Pharmaceuticals LLC (SPL) will develop drugs to treat impulsivity, violence and self-injurious behavior in patients with autism, Tourette's syndrome, and mental retardation. These drugs, terme ...

    STTR Phase I 2002 Department of Health and Human Services
  6. TREATING SELF-ABUSE IN AUTISM AND MENTAL RETARDATION

    Amount: $498,684.00

    Serenix Pharmaceuticals LLC (SPL) will develop drugs to treat impulsivity, violence and self-injurious behavior in patients with autism, Tourette's syndrome, and mental retardation. These drugs, terme ...

    STTR Phase II 2002 Department of Health and Human Services
  7. Screening New Therapeutics for the Treatment of Post Traumatic Stress Disorder

    Amount: $141,071.00

    DESCRIPTION (provided by applicant): Project Summary/Abstract Post-traumatic Stress Disorder (PTSD) is recognized by the NIMH, the Department of Defense, and the Veterans' Administration as ...

    STTR Phase I 2011 Department of Health and Human Services
  8. New Drugs for Stress-related Affective Illness

    Amount: $1,794,075.00

    DESCRIPTION (provided by applicant): Vasopressin (AVP) antagonists represent a novel therapeutic class for the treatment of depression. The potential utility of these compounds has emerged from observ ...

    SBIR Phase II 2011 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government